Home › Interstitial Lung Diseases
Interstitial Lung Diseases clinical trials recruiting in the U.S.
53 studies for Interstitial Lung Diseases are recruiting participants at sites across the United States.
Interstitial lung diseases are a group of diseases that inflame or scar the lungs. Breathing in particles (asbestosis, silicosis) causes some types.
Cities with the most studies
- New York City, NY18 studies
- Philadelphia, PA16 studies
- Los Angeles, CA14 studies
- Kansas City, KS13 studies
- Durham, NC13 studies
- Charleston, SC13 studies
- Chicago, IL12 studies
- Houston, TX12 studies
- Aurora, CO11 studies
- Ann Arbor, MI11 studies
- Phoenix, AZ9 studies
- Salt Lake City, UT9 studies
- Boston, MA9 studies
- Rochester, MN9 studies
- Dallas, TX9 studies
- Birmingham, AL9 studies
- Orlando, FL9 studies
- Cincinnati, OH8 studies
- Tampa, FL8 studies
- Minneapolis, MN8 studies
- Bend, OR7 studies
- San Francisco, CA7 studies
- Richmond, VA6 studies
- Washington, DC6 studies
- Indianapolis, IN6 studies
- Denver, CO6 studies
- Gainesville, FL5 studies
- Naples, FL5 studies
- Columbus, OH5 studies
- Jacksonville, FL5 studies
- Oklahoma City, OK5 studies
- Winston-Salem, NC5 studies
- Albuquerque, NM5 studies
- Cleveland, OH5 studies
- Nashville, TN5 studies
- Pittsburgh, PA5 studies
- Scottsdale, AZ4 studies
- New Haven, CT4 studies
- Rochester, NY4 studies
- Greensboro, NC4 studies
By state
- Alabama9 studies
- Arizona13 studies
- California22 studies
- Colorado15 studies
- Connecticut4 studies
- District of Columbia5 studies
- Florida24 studies
- Georgia3 studies
- Illinois12 studies
- Indiana6 studies
- Kansas13 studies
- Kentucky4 studies
- Louisiana5 studies
- Maryland5 studies
- Massachusetts11 studies
- Michigan16 studies
- Minnesota14 studies
- Mississippi3 studies
- Missouri6 studies
- Nevada4 studies
- New Jersey3 studies
- New Mexico5 studies
- New York20 studies
- North Carolina18 studies
- Ohio14 studies
- Oklahoma5 studies
- Oregon9 studies
- Pennsylvania18 studies
- South Carolina14 studies
- Tennessee7 studies
- Texas18 studies
- Utah9 studies
- Virginia8 studies
- Wisconsin4 studies
Recently updated studies
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 30, 2026 · NCT07201922Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07179380LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT07613099Pulmonary Fibrosis Foundation Community Registry
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05382572A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07323732A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 11, 2026 · NCT07816185SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
Recruiting
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07269262A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 8, 2026 · NCT07473700A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 2, 2026 · NCT07285655A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 2, 2026 · NCT07333183Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT00258583DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07486869PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Aug 18, 2026 · NCT06855329Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RecruitingPhase 2
Ages 8 to 60 · All sexes · Updated Aug 14, 2026 · NCT03630211An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT07234032From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.